NEOV NeoVolta Inc. Insider Trading

EVP Steve Bond buys 43.0K shares of NEOV at $1.99; stock now -70.6% from 52-week high of $7.13

Steve Bond, Executive Vice President of NeoVolta Inc., purchased 43,000 shares at $1.99 on 2026-06-01, bringing his total holdings to 840,000 shares. The timing of this purchase is notable: the stock has declined 22.8% over the past 30 days and 37.5% over the past 90 days, trading at $2.10 currently, which is 70.6% below its 52-week high of $7.13. However, Bond's track record with open-market purchases across all tickers shows an average 90-day return of -5.2% with a 0.00% win rate, and his single prior purchase at NEOV on 2026-05-19 also produced a -5.2% 90-day return, establishing a pattern of poorly-timed entry points. The company itself is unprofitable, reporting a net loss of $3,028,402.00 in the latest quarter against quarterly revenue of $2,023,718.00, though it achieved 218.6% annual revenue growth year-over-year. The fundamental disconnect between rapid growth and persistent losses, combined with the insider's poor historical timing on entry decisions, warrants investor scrutiny of the underlying business trajectory.

EVP Bond Steve buys 47,000 NEOV shares at $2.09; stock down 68.3% from 52-week high, company unprofitable.

Bond Steve, Executive Vice President of NeoVolta, purchased 47,000 shares at $2.09, increasing his holdings from 750,000 to 797,000 shares. The transaction occurs as the stock trades 68.3% below its 52-week high of $7.13 and has declined 27.6% over 30 days and 37.4% over 90 days. NeoVolta reported positive revenue growth of 218.6% year-over-year and generated $2.0M in latest quarterly revenue, but remains unprofitable with a full-year net loss of $-3.0M. The purchase amounts to a 6.3% increase in his position at substantially depressed price levels relative to recent highs, occurring during a period of significant stock weakness, though without additional context on strategic plans or capital structure this action by itself does not conclusively signal near-term recovery expectations.